Concentration-Response Analysis of the Combination of Pyronaridine and Piperaquine on Corrected QT Interval From a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults of African Sub-Saharan Origin.

ABSTRACT: A novel oral combination of the long-acting antimalarials pyronaridine (PYR) and piperaquine (PQP) has potential for malaria chemoprevention. This single-center randomized, double-blind, placebo-controlled study assessed the effects of PYR and PQP alone and when co-administered on Fridericia-corrected QT interval (QTcF). Between February 14, 2022, and May 31, 2022, thirty-seven healthy black adults of African sub-Saharan origin were enrolled and randomized to PYR + PQP (n = 15), PYR + placebo (n = 8), PQP + placebo (n = 8) or double placebo (n = 6) administered once daily (fasted) for 3 days at doses approved for malaria treatment. Triplicate digitalized electrocardiogram (ECG) recordings and pharmacokinetic samples were taken at matched timepoints. Concentration-response analysis was perf

SUBMITTER: Felices M 

PROVIDER: S-EPMC12278333 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature